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Abstract: Public health responses to HIV epidemics have
long relied on epidemiological modelling analyses to help
prospectively project and retrospectively estimate the
impact, cost-effectiveness, affordability, and investment
returns of interventions, and to help plan the design of
evaluations. But translating model output into policy
decisions and implementation on the ground is chal-
lenged by the differences in background and expectations
of modellers and decision-makers. As part of the PLoS
Medicine Collection ‘‘Investigating the Impact of Treat-
ment on New HIV Infections’’—which focuses on the
contribution of modelling to current issues in HIV
prevention—we present here principles of ‘‘best practice’’
for the construction, reporting, and interpretation of HIV
epidemiological models for public health decision-making
on all aspects of HIV. Aimed at both those who conduct
modelling research and those who use modelling results,
we hope that the principles described here will become a
shared resource that facilitates constructive discussions
about the policy implications that emerge from HIV
epidemiology modelling results, and that promotes joint
understanding between modellers and decision-makers
about when modelling is useful as a tool in quantifying
HIV epidemiological outcomes and improving prevention
programming.
Introduction
In almost all areas of public health, mathematical models are
used to provide quantification and insight that can inform
decision-making. Epidemiological data can be collected about
individuals, and clinical trials can measure individual-level effects
in a selected study population (often under best-case circum-
stances), but public health decision-making requires an under-
standing of the dynamics of disease across a population under a
variety of conditions. Mathematical modelling aims to unite
knowledge and assumptions about behavioural dynamics,
biology, costs, and constraints to generate estimates of impact
and cost-effectiveness, and recommendations for resource
allocation.
Models are especially useful in the case of infectious diseases,
where they can estimate temporal changes in disease burden and
treatment needs, and so underpin projections of the counter-
factuals in some quasi-experimental impact evaluation designs,
and power calculations for prospective experimental study designs.
These are important applications, especially in contexts where
empirical data are not available. Thus, models have increased in
prominence over the last several years, including in establishing
optimal responses to emerging pathogens [1] and influenza
pandemics [2], examining the conditions for polio eradication
[3] and malaria control [4], and making a case for restructuring
investment in HIV programs [5,6].
Investigators from many different disciplines generate models,
and the techniques and presentation formats employed have
tended to follow a corresponding diverse set of conventions and
presumptions. Meanwhile, those who rely on modelling output
have highly varied needs and expectations from epidemiological
modelling analyses. It is not uncommon for different models
addressing very similar questions to produce—or appear to
produce—widely different estimates [7], and thus a model’s
validity and ability to inform an important public health decision
can be questioned.
Therefore, there is a need for constructive dialogue between
‘‘producers’’ and ‘‘consumers’’ of modelling results about a
model’s assumptions and structure, the policy implications of the
results, and what further empirical and modelling studies should
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funder, coordinator, and evaluator of HIV prevention efforts, has
become increasingly reliant on mathematical modelling and has
initiated a modelling guidelines development process through its
Prevention Science and Mathematical Modelling Reference
Group, a panel of experts in HIV prevention, and modelling
relating to HIV prevention, created and convened by the World
Bank on the basis of individuals’ publication records and
institutional roles. In consultation with the reference group and
other HIV modelling experts, we have developed a set of
principles for the construction, reporting, and interpretation of
HIV epidemiological models for public health decision-making on
all aspects of HIV.
Development and Scope of the Recommendations
The nine principles, discussed below and summarised in
Table 1, were initially identified during a number of discussions
within the context of collaboration amongst the authors, within the
HIV Modelling Consortium and the World Bank modelling
guidelines production process. Written input on the nine principles
was solicited from a wider group of modellers, including former
and current collaborators. This was followed by a three-day work
retreat of five of the authors, during which a first draft was
produced, based on the authors’ experience and other researchers’
responses to the proposed core principles. The resulting draft was
presented to a meeting of the World Bank Prevention Science and
Mathematical Modelling Reference Group, and revised in light of
feedback received.
Our focus complements more general reviews of modelling [8–
10] and technical content in modelling textbooks [11,12]. The
recommendations are intended for all HIV public health
practitioners who rely on modelling research to make policy
decisions, as well as those conducting the modelling research itself.
They are not intended to be prescriptive, and hence should not be
seen as a normative checklist against which to score the quality or
validity of modelling studies. For instance, where mathematical
models are used to construct a simple conceptual framework of
behavioural, clinical, virological, and/or epidemiological dynam-
ics, rather than to conduct research for public health decision-
making, some of the recommendations in this article may not be
applicable.
Principle 1: Clear Rationale, Scope, and Objectives
As in any scientific report, the rationale, scope, and objectives
of a modelling study should be clearly stated. The reporting of a
modelling study should include an explicit explanation for why
epidemiological modelling, rather than another study design
(e.g., systematic review, meta-analysis, quasi-experimental de-
sign, or a randomized controlled trial), is appropriate for the
problem, the exact questions the work seeks to address, and the
readership for which it is intended. This statement of rationale,
scope, and objectives provides the criteria against which all
modelling decisions should be judged, assists in framing the
interpretation of the work, and should be referred to at key
points throughout the write-up, to maintain the alignment of
a i m s ,m o d e l ,r e s u l t s ,a n di n t e r p r e t a t i o n .E x a m p l e sm i g h tb e :
‘‘We aimed to generate estimates for the cost of rolling out a
male circumcision programme in South Africa so that stake-
holders can compare these costs against those of other possible
interventions, and use the comparison to inform decisions about
allocation of funding’’; ‘‘We aimed to explore the extent to which
HIV incidence rates can be influenced by changes in condom
use among sex workers and their clients under different
assumptions about sexual mixing patterns in concentrated HIV
epidemics, so that recommendations can be made for data
collection during the implementation of a condom distribution
campaign’’.
For studies that aim to estimate the potential population-level
impact of a given biomedical intervention, there are differences in
emphasis in their purpose that should be clear from the outset and
throughout the presented work. An important distinction is
between investigation of the potential benefits of a hypothetical
biomedical intervention that is currently in development but has
unknown efficacy, and an intervention that has a proven efficacy,
such as from a trial setting. Typically, the purpose of the first type
of study is to estimate the population-level effectiveness of the
hypothesized intervention and to identify key properties the
intervention would need to have to be effective (such as for
vaccines [13–15], microbicides [16,17], and chemoprophylaxis
[18]), whereas the purpose of the second type of study is to guide
targeted implementation of the intervention in real populations
(such as deciding which populations should be circumcised first
[19], or prioritised for treatment as prevention [20]). Another
distinct form of modelling study is where an assessment is
generated for the epidemiological impact of a previously
implemented public health program [21].
Principle 2: Explicit Model Structure and Key
Features
The model chosen for the analysis should be described
completely and clearly (commonly in the form of an online
technical appendix, ideally with the model’s computer code
made available), so that other investigators can reproduce its
findings and projections. Justification for the choice of model
(individual- versus population-based, stochastic versus deter-
ministic, linear versus nonlinear) should be provided, along
with a description of the model’s structure and key features,
with cross-references to the scope and objectives. A flow
diagram, representing how individuals or subpopulations
transition through the different demographic, behavioural,
or clinical states in the model can be an excellent way to
communicate the model’s main structure.
The model structure, and the consequent key demographic,
behavioural, biological, clinical, and epidemiological factors
represented or omitted by the model, may affect the interpretation
of the results. Certain biological or behavioural features of HIV
transmission, prevention, and treatment may be at the core of the
issue addressed by the model, and cannot be omitted. However,
additional features that are irrelevant to the primary objectives of
the analysis may obscure the main conclusions or may open
unnecessary debate about the validity of parameter values that are
not essential to interpretation of the model output [8]. Judging
which features fall into which category may be informed by earlier
research or explicit investigation, but is more commonly based on
assumptions, which should at least be clearly stated. Furthermore,
a mathematical model need not require an examination at all
scales (e.g., within host, individual level, sexual network level, and
population level); rather, scales to be included should be dictated
by the objectives of the study (e.g., some models focus on within-
host processes and thus must include the interaction between virus
and immune cells, but models that focus on between-host
transmission may not require detail at this scale). In general, the
strength of the model should not be judged merely by the level of
model detail and whether or not particular factors are included.
Rather, the appropriateness of model detail and factors taken into
PLoS Medicine | www.plosmedicine.org 2 July 2012 | Volume 9 | Issue 7 | e1001239account by the model should be assessed within the context of the
scope and objectives.
Discussion of how the model structure could have influenced the
results should always be included. Examples of formal evaluations
of differently structured models addressing similar research
questions but reaching different conclusions can be found in
various branches within the infectious disease modelling field, e.g.,
in the modelling of chlamydia [22], influenza [23], and HIV
epidemics [24]. It is often not feasible, in one article or within one
modelling research group, to explore large differences in model
structure, such as between deterministic population-based versus
individual-based models. However, where possible, comparison
between models is highly encouraged. For example, Johnson et al.
[25] used two models in the same study to assess the impact of
antiretroviral therapy (ART) and condom usage on HIV
epidemics in South Africa, and Eaton et al. [7] discuss the
implications of alternative model structures for estimating the
potential impact of early initiation of ART on HIV incidence in
hyperendemic settings. Such formal evaluations foster discussions
of the reasons behind discrepancies in model predictions, and
either pave the way for a consensus statement about the findings
and conclusions that are most certain, or highlight key issues for
further scientific enquiry.
Principle 3: Well-Defined and Justified Model
Parameters
Anothersetofassumptionsinamodelconcernsthevaluesthatare
given to the parameters. Examples of parameters include the
probability of HIV transmission per sex act for an individual on
Table 1. Summary of principles of good HIV epidemiology modelling.
Principle Model Producer Considerations Model Consumer Considerations
Clear rationale, scope, and objectives Are the rationale, scope, and objectives clearly stated? Are the rationale, scope, and objectives understood?
Is there a statement about why epidemiological
modelling is appropriate for this problem?
Is epidemiological modelling appropriate for this problem?
Explicit model structure and key
features
Is the model structure completely described, such
that all analyses can be reproduced?
Is the model presented comprehensively, such that the
inclusion/exclusion of any particular assumption or feature can
be identified?
Is there a description of key model features? Is the justification for model structure/key assumptions
reasonable, considering the primary rationale, scope, and
objectives of the study?
Has a justification for the model structure been provided?
Well-defined and justified model
parameters
Is there an understandable and complete listing of the
model parameters, their values, and their justification?
Are the implicit inputs upon which the model predictions are
made understood, and are they satisfactorily justified?
Alignment of model
output with data
Are the model fitting, calibration, and validation
approaches with respect to relevant data defined and
justified?
Does the model produce, or fail to produce, outputs that can
be compared to real world data, and does the model output
reflect realistic conditions?
Does the comparison with real world data increase confidence
in the suitability of the model for the current enquiry?
Clear presentation of results,
including uncertainty in estimates
Have the uncertainties been captured for all relevant
factors included in the model?
Have the uncertainties been captured for all relevant factors
included in the model?
Is the key result of the study robust to that uncertainty? Are the results sufficiently robust for confident decision-
making, or is further analysis or data collection required?
Are specific recommendations for new data analyses/
collections appropriate?
Exploration of model limitations Are sufficient details provided about limitations of the
study, specifically about model structure,
parameterization, and application/generalisability?
Are the limitations of the model and its findings clearly
understood, including the limits of applicability and
generalisability?
Considering the strength of the evidence, how are the model
findings relevant for informing public health decision-making?
Contextualisation with other
modelling studies
Have relevant previous studies been referenced and
differences/similarities discussed?
Is there an understanding of the overarching conclusion(s) from
modelling studies on the topic?
Is it clearly specified whether a new result versus a
confirmation/contradiction of a previous result is
presented?
Are the general reasons (assumptions or underlying real world
conditions) for why models differ in their conclusions
understood?
Application of epidemiological
modelling to health economic
analyses
Where relevant, are understandable and appropriate
estimates of epidemiological impact provided, such
that health economic inferences can be made?
Can the model-based estimates be used to infer cost-
effectiveness measures of relevant interventions or be
extended to health economics?
Is the degree of uncertainty in estimates relevant to cost-
effectiveness understood, particularly with respect to the
sensitivity of key parameters?
Clear language Are model scenarios described in clear formal terms
(separate from interpretations about reality) that
facilitate technical understanding and evaluation?
Are there clear explanations of intended correspondences
between inputs used in the model and key real world
conditions such as epidemiological conditions, policy, and
programmes?
doi:10.1371/journal.pmed.1001239.t001
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ART initiation, and the annual population growth rate. It is essential
for any modelling study to include a transparent listing of all model
parameters, providing the following for each parameter: the name of
the parameter; the mathematical symbol of the parameter (if
appropriate); the meaning of the parameter in plain language; the
value(s) assigned to the parameter (a point estimate and range/
confidence interval as appropriate); and a contextual justification for
usedvalues,with referencesfor theorigins of themodel parameter(s),
and any relevant caveats (particularly important if more than one
value for the model parameter exists or if the parameter is fit in the
model or is derived from another modelling analysis).
This notion of justifying or formally ‘‘fitting’’ individual
parameters—or a model in its entirety—to data covers many
possibilities. As these also do not lie on a clear continuum from
‘‘rough heuristic/qualitative’’ to ‘‘formally rigorous and unbiased’’,
some ad hoc critical evaluation is appropriate for the most
important inputs into any model. All model fitting relies on the
notion of the likelihood of observing a set of data. There are then
various possible approaches to (1) maximising the likelihood, i.e.,
selecting the particular model within which the data are most
consistent, or (2) performing a sensitivity analysis, i.e., identifying
ranges of model parameters that are consistent with the data and
determining the relative importance of each model parameter. Note
that the ‘‘likelihood function’’ itself can capture multiple sources of
randomness, such as the usually unavoidable incompleteness of
sampling and random effects in population processes themselves.
Some parameters, such as the mother-to-child HIV transmission
rate under a particular care regimen, can be more or less directly
‘‘measured’’ in an appropriate (typically randomized) study, using
observation and standard robust biostatistical methods, but there
may be subtle artefacts. For example, using logistic regression to
identify the characteristics of individuals that are associated with an
HIV infection or transmission event may be misleading in ways that
are seldom systematically explored in routine application, beyond
noting the potential for ‘‘residual confounding’’. A particular shape
for a relationship between a predictor (such as viral load or age) and
an outcome (transmission) is implicitly assumed, although it may be
inappropriate—age in particular may correlate strongly with health
status, but not necessarily monotonically.
For parameters where it is very difficult to obtain direct
measurements, e.g., to capture behavioural dynamics such as risk
reduction in the face of risk perception, heuristic parametrization
may indicate which parameter sets are plausible and which are
clearly at odds with data: a heuristically sensible model and a
formally fitted model should be clearly distinguished, with
sensitivity analyses where applicable.
Often the most important assumptions concern those specifying
a simulated intervention, and it is recommended that these be
prominently and exhaustively listed. For instance, if the interven-
tion of interest relates to a policy change in ART, specifying a
‘‘coverage’’ and ‘‘efficacy’’ may not be enough: assumptions about
enrolment rates, adherence, and retention, as well as behavioural
characteristics (e.g., risk reduction or compensation) and demo-
graphic impacts (e.g., reduced mortality rates and increased size of
the HIV-positive population) [7] may need to be made explicit.
These specifications should be documented over the time period of
the model simulation, and, where relevant, for different substrata
of the modelled population. If the work is specific to a country,
then it is helpful to involve relevant stakeholders in the decisions
taken about parameter values, and this process should be
described. Such documentation also assists when modelling
findings are subsequently used to inform decision-making in that
setting [26,27].
Principle 4: Alignment of Model Output with Data
Here the emphasis shifts to assessing the alignment of output
from a particular epidemiological scenario model to data.
Understanding the modelled scenarios produced, and relating
these to data by back-fitting them to a model, naturally forms an
important component of the evaluation and application of any
model. It is particularly important to indicate whether, and to
what extent, input parameters were chosen to maximise the
correspondence of outputs to data, or whether correspondences
emerged naturally from choosing externally justified inputs.
Demonstrating that a model can reproduce observed patterns
provides a certain level of reassurance that the model is capturing
the system appropriately, and where models cannot demonstrate
this, extreme caution should be taken in interpreting results.
The most desirable situation is when a model that has been
fitted to some data (a training set) produces output in close
correspondence with additional data (a testing set). There are two
primary caveats to this approach: (1) fitting a smooth model to
slowly varying data and extrapolating a little may be ‘‘too easy’’,
and might indicate little about the suitability of the model, and (2)
in key applications relevant to impact evaluation, asking the model
to produce other independent data may be an unreasonable
demand, tantamount to asking a model to predict future changes
in the financial or political context. There may be deeper
differences between the scenarios producing the training/testing
datasets than can realistically be captured by a model—such as
changes in treatment uptake or effects of improved treatment
programmes on mortality.
While correspondence between models and data is reassuring
and potentially useful—if not taken as absolute confirmation of the
correctness of either model structure or parameter values—it is
important to consider whether there are multiple ways to fit the
data, and to realise that there may be scientific progress in a failure
to fit data, either at all or without resorting to implausible values,
ranges, or correlations of parameters. For example, simple
(biological) models of ART cannot reproduce both the consistently
strong reductions in patient viral loads and the inability to achieve
viral eradication observed in the real world, without implausible
‘‘fine tuning’’ of individual subjects’ treatment efficacy parameters
into a narrow range. This situation diagnoses a model limitation,
namely, the neglect of the fact that interactions between cells,
drugs, and virions vary among compartments within the infected
host.
The difficulties of ‘‘correctly’’ capturing a complex set of shifting
context-defining processes impinge not only on the interpretation
of correspondence between models and historical data, but also on
the interpretation of the predictive component of scenarios. One
useful application of modelling, when there are insufficient data to
construct scenarios with conventional predictive credibility, is to
pose questions such as what characteristic of a program would be
required for certain goals to be achieved (e.g., what level of risk
compensation, captured in a suitably clearly defined parameter,
would be required to negate the risk reduction of a planned
intervention).
Principle 5: Clear Presentation of Results,
Including Uncertainty in Estimates
The output of any modelling study needs to be presented clearly,
using explicitly defined metrics and with any deviance in the
interpretation between the model metric and the real world
analogue explained. The many assumptions involving the structure
of the model, the parameter estimates, and the data will all have
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to key model outputs. In some cases, uncertainty in a particular
parameter will be benign—a result is reached irrespective of any
credible assumption about that parameter—and this serves to
increase confidence in the findings. In other cases, different credible
values for a parameter (or model structure or interpretation of data)
would lead to different conclusions, and this should be noted.
Uncertainties are best depicted as part of the modelling results
presentation—either in tables or as part of the graphical output of
the model. If sufficient information is available about inputs,
computational techniques can manufacture a distribution for
model outcomes, so that the main result can be given as a
‘‘credible interval’’. In addition to uncertainty analyses, formal
sensitivity analyses of the importance of each model parameter in
influencing the variability in model outcomes can be useful for
identifying items for further data collection or investigation (see
[28–30] for examples in HIV modelling). Bayesian melding
approaches have also been used recently, and have the advantage
that they integrate uncertainty analyses with model fitting: good
examples in HIV transmission modelling include work by Alkema
et al. [31] and Johnson et al. [32].
Principle 6: Exploration of Model Limitations
As Box and Draper [33] wrote, ‘‘Remember that all models are
wrong; the practical question is how wrong do they have to be to
not be useful’’. It is necessary for modellers to provide a
description of model limitations and for model consumers to
appreciate the caveats and limitations of modelling studies when
considering their results. Many limitations are due to the data that
are available and used to parameterize modelling studies. Direct
observation of some of the model parameters is often not feasible.
This is especially true in the case of HIV, where transmission
dynamics are dependent on sensitive and private aspects of human
behaviour [34]. Modelling strategies address this challenge in part
by fitting the model to data to yield estimates for the unknown
parameters.
One thing that modellers may implicitly understand but that
model consumers may not—and which therefore should always be
made clear—is that capturing complex reality is not really the
purpose of mathematical models. Practicality implies that one can
never capture full dynamical structure, such as all conceivable
population compartments, transition rules, or stochasticity. A
mathematical model is a minimalist approach to representing the
essential elements of reality that are necessary and sufficient for
addressing a specific research question [35,36]. Models are often
applied to specific settings, and so transferability of the predictions
to other settings may be limited. Just as the findings of clinical trials
can be subject to multiple interpretations, modelling studies
similarly may have multiple interpretations, and even more readily
admit various choices in emphasis, of which only a few receive a
full airing in the investigators’ report.
Some of the limitations of modelling studies can be addressed by
uncertainty or sensitivity analyses as discussed above [28,37,38].
Probably the least appreciated mode by which limitations in
models are addressed is by a comparative assessment of models
and their predictions, similar to systematic reviews and meta-
analyses of datasets. Recent examples of this kind of process
include the male circumcision modelling consensus paper [19], a
special edition of Vaccine that examined the potential impact of a
partially effective vaccine [13], and model comparisons of the
impact of ART on prevention presented in another article in the
July 2012 PLoS Medicine Collection, ‘‘Investigating the Impact of
Treatment on New HIV Infections’’ [7].
Principle 7: Contextualisation with Other
Modelling Studies
It is common for multiple modelling groups to attempt to
address similar research questions but with different modelling
approaches: using models that have been designed to describe
different populations, involve different model structures, and make
different parameter assumptions. Apparently conflicting results in
the modelling literature may consequently lead to greater
confusion for the consumers of models or to distrust in the use
of models for decision-making. Therefore, it is necessary that
interpretations of results are contextualised with previous model-
ling findings relevant to the topic. It should be made clear whether
a new result is being presented or whether study findings concur
with previously published results.
Meanwhile, journal editors should recognise the value of works
that rigorously confirm or draw together previous findings. Review
papers that summarise the modelling literature on a specific topic
are highly useful (see the recent special issue on HIV epidemic
modelling in Current Opinion in HIV and AIDS [39]). Also, papers
that aim to present meta-analyses of model results (e.g., [24])
should be encouraged, as well as papers that compare modelling
results to quasi-experimental results. Of even greater utility for
policy-makers is the formulation of consensus documents that
summarise conclusions from numerous modelling studies, and
provide general conclusions in a single voice from the modelling
community; this has been done for evaluations of circumcision
interventions [19] and HIV vaccines [13], and this PLoS Medicine
Collection on HIV treatment as prevention aims to move the field
in that direction as well, although there is clearly much more to do
[7,40].
Principle 8: Application of Epidemiological
Modelling to Health Economic Analyses
A public health policy or programme decision-maker generally
desires to take actions that will have maximal impact whilst
minimising the amount of money required to achieve the health
outcomes—based, for example, on estimates of either the
maximum impact that can be achieved for a given amount of
money, or the money needed to achieve specific set levels of
impact. Therefore, the cost-effectiveness, affordability, and returns
on investments of interventions are among the most important
considerations in their potential implementation. HIV epidemic
modelling studies often attempt to estimate the population-level
impact associated with changes in programme or policy condi-
tions, and hence estimate the denominator (effectiveness) in the
incremental cost-effectiveness ratio. Ideally, such models should be
designed to produce outputs amenable to recycling into analyses
of cost implications and estimates of primary epidemiological
effects that are understandable and relevant to decision-makers,
such as the number of incident infections or deaths averted,
quality-adjusted life years gained, or disability-adjusted life years
averted. Effective assessment of affordability and cost-effectiveness
may require different time horizons than those chosen in
epidemiological modelling analyses, hence additional simulations
may be necessary prior to attaching costs, benefits, and utilities to
epidemiological model outputs.
There are numerous good examples of modelling studies that
have provided outputs that are relevant for use in health economic
calculations or that have been integrated into cost-effectiveness
analyses [41–44]. Guidelines have been developed for the
production, submission, and review of health economic analyses
for BMJ [45]; some of the principles presented in those guidelines
PLoS Medicine | www.plosmedicine.org 5 July 2012 | Volume 9 | Issue 7 | e1001239align with those presented here. When modelling studies have the
potential to be extended to health economic calculations,
consideration of these health economic guidelines is encouraged.
Principle 9: Clear Language
A particular challenge that arises when using models to evaluate
the impact of interventions is a lack of clarity around the
intervention itself. Such a lack of clarity minimises the usefulness
of results for policy-makers in deciding which interventions to
prioritise. While modellers are usually keenly aware of the technical
details of the model, the interpretation of model features—both in
the input and output phase—is prone to oversimplification by both
modellers and readers. It can be convenient but misleading to
present a correspondence in the real world between an actual policy
choice and future events. For instance, a write-up should highlight
that what is modelled is a reduction in the proportion of
‘‘unprotected sex acts’’, which is not an intervention per se but
could be the outcome of an intervention (e.g., an increase in
condom distribution points or a targeted education campaign).
It is probably better to risk erring on the side of repetitiveness in
efforts to keep focusing on precise model assumptions (qualitative
and quantitative), and for consumers to process the model first on
its own terms, before evaluating model scenarios in broad
correspondence to reality and potential policy implications. At
the same time, it is important that modellers use language that
facilitates easy communication, without loss of precision and of key
real world messages to consumers.
Conclusion
The issue of using models in decision-making is especially
important for the field of HIV prevention, which has now reached
a critical point. Just as spending on HIV has levelled off or
declined [46], there have been several significant scientific
breakthroughs, including the finding that ART can substantially
reduce the infectiousness of infected individuals [47]. This finding
immediately conjures a multitude of questions that can be best
examined through mathematical modelling. Examples of specific
questions within the field would include (1) whether programs
should reallocate funding to treatment in response to the new data
[48], (2) the probability of drug resistance emerging as a threat to
the therapeutic effectiveness of treatment [49], and (3) how the
impact of real programs can be scientifically measured [50].
Further research questions are delineated in this PLoS Medicine
Collection [40]. Our intention in compiling our recommendations
is to help strengthen the support that mathematical models can
provide in addressing such questions that are critical for setting
research and intervention priorities for HIV.
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